PL410950A1 - Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV - Google Patents

Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV

Info

Publication number
PL410950A1
PL410950A1 PL410950A PL41095015A PL410950A1 PL 410950 A1 PL410950 A1 PL 410950A1 PL 410950 A PL410950 A PL 410950A PL 41095015 A PL41095015 A PL 41095015A PL 410950 A1 PL410950 A1 PL 410950A1
Authority
PL
Poland
Prior art keywords
hbv virus
vaccine against
against hcv
vaccine
immunogenic vaccine
Prior art date
Application number
PL410950A
Other languages
English (en)
Other versions
PL230663B1 (pl
Inventor
Anna Czarnota
Katarzyna Grzyb
Original Assignee
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Gdański filed Critical Uniwersytet Gdański
Priority to PL410950A priority Critical patent/PL230663B1/pl
Priority to PCT/PL2016/000002 priority patent/WO2016114676A1/en
Priority to EP16705838.7A priority patent/EP3244921B1/en
Priority to PL16705838T priority patent/PL3244921T3/pl
Publication of PL410950A1 publication Critical patent/PL410950A1/pl
Publication of PL230663B1 publication Critical patent/PL230663B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem wynalazku jest szczepionka, która zawiera determinantę "a" białka HBsAg wirusa HBV subtypu adw2 wraz z rejonem 412-425 glikoproteiny E2 osłonki wirusa HCV. Ujawniono również wyizolowane chimeryczne białko w postaci szczepionki, zestaw zawierający chimeryczne białko oraz sposób otrzymywania szczepionki. Ponadto przedmiotem wynalazku jest kompozycja zawierająca chimeryczne białko oraz wektor ekspresyjny.
PL410950A 2015-01-15 2015-01-15 Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV PL230663B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL410950A PL230663B1 (pl) 2015-01-15 2015-01-15 Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
PCT/PL2016/000002 WO2016114676A1 (en) 2015-01-15 2016-01-14 An immunogenic vaccine against the hcv and/or hbv
EP16705838.7A EP3244921B1 (en) 2015-01-15 2016-01-14 An immunogenic vaccine against the hcv and/or hbv
PL16705838T PL3244921T3 (pl) 2015-01-15 2016-01-14 Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL410950A PL230663B1 (pl) 2015-01-15 2015-01-15 Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV

Publications (2)

Publication Number Publication Date
PL410950A1 true PL410950A1 (pl) 2016-07-18
PL230663B1 PL230663B1 (pl) 2018-11-30

Family

ID=55405413

Family Applications (2)

Application Number Title Priority Date Filing Date
PL410950A PL230663B1 (pl) 2015-01-15 2015-01-15 Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
PL16705838T PL3244921T3 (pl) 2015-01-15 2016-01-14 Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16705838T PL3244921T3 (pl) 2015-01-15 2016-01-14 Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV

Country Status (3)

Country Link
EP (1) EP3244921B1 (pl)
PL (2) PL230663B1 (pl)
WO (1) WO2016114676A1 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CU23011A1 (es) 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
ES2456961T3 (es) * 2007-02-21 2014-04-24 University Of Massachusetts Anticuerpos humanos contra el virus de la hepatitis C (VHC), usos de los mismos
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv

Also Published As

Publication number Publication date
EP3244921B1 (en) 2019-08-28
EP3244921A1 (en) 2017-11-22
PL230663B1 (pl) 2018-11-30
WO2016114676A1 (en) 2016-07-21
PL3244921T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EP3710049A4 (en) THERAPEUTIC HEPATITIS B VIRUS (HBV) VACCINE USING PRES1 AND / OR PRES2 AND / OR S-HBSAG REGIONS OF HBV OF HBV ENVELOPE PROTEIN
EA201692274A1 (ru) Олигомеры и олигомерные конъюгаты
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA201790717A1 (ru) Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
PH12019500788A1 (en) Engineered meganucleases specific for recgonition sequences in the hepatitis b virus genome
EP3439696A4 (en) THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN
EA201892735A1 (ru) Состав вакцины против hiv
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
EA202190778A1 (ru) Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
BR112018000037A2 (pt) partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina
MX2019007924A (es) Vacunas contra la influenza.
MX2015010366A (es) Parvovirus porcino 5b, metodos de uso y vacuna.
IN2015DN03925A (pl)
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
PL410950A1 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV